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Abstract
Background: We evaluated the impact of different case definition algorithms on the prevalence of paediatric
inflammatory bowel disease (IBD), Crohn’s disease (CD) and ulcerative colitis (UC) and to compare the occurrence of
certain diseases compared to matched controls.
Methods: Paediatric patients (<18 years) were identified via ICD codes for UC and CD in Swedish registers between
1993 and 2010 (n = 1432). Prevalence was defined as ≥2 IBD-related visits. Prevalence of treated children in 2010
was defined as ≥2 IBD-related visits with one visit and ≥1 dispensed IBD-related drug prescription in 2010. To test
the robustness of the estimates, prevalence was also calculated according to alternative case definitions. The
presence of rheumatic, hepatobiliary, pancreatic, and dermatologic diseases were compared with age-/sex-/county-of-
residence-matched general population controls.
Results: The IBD prevalence was 75/100,000 (CD: 29/100,000; UC: 30/100,000; patients with IBD-U: 16/100,000).
Prevalence of treated disease in 2010 was 62/100,000 (CD: 23/100,000; UC: 25/100,000; patients with IBD-U: 13/100,000).
When age restrictions were employed, the prevalence estimate decreased (<17y: 61/100,000, <16y: 49/100,000 and
<15y: 38/100,000).
Compared to general population controls (n = 8583), children with IBD had a higher prevalence of dermatologic
(4.7% vs. 0.6%), hepatobiliary (including primary sclerosing cholangitis) (5.5% vs. 0.1%), pancreatic (1.7% vs. 0%) and
rheumatic diseases (7.2% vs. 1.2%; all P < 0.01).
Conclusions: The overall prevalence of paediatric IBD in Sweden was similar to that in earlier regional cohorts. IBD
patients had a higher prevalence of comorbid conditions than matched general population controls.
Keywords: Prevalence, Paediatrics, Inflammatory bowel disease, Crohn’s disease, Ulcerative colitis, Sweden
Background
Inflammatory bowel disease (IBD) is a group of chronic
inflammatory disorders, mainly affecting the gastrointes-
tinal tract with extraintestinal manifestations and associ-
ated immune disorders. It is usually divided into the
phenotypes Crohn’s disease (CD), ulcerative colitis (UC)
and IBD unclassified (IBD-U, a form of colonic IBD
whose features make it impossible to define as either CD
or UC at diagnosis). IBD is associated with substantial
morbidity and decreased quality of life in patients [1].
The frequently intensive disease course results in signifi-
cant use of healthcare resources including outpatient
visits, hospitalization and surgery [2].
Although most patients are adults, some 10–25% are
diagnosed before 21 years of age [1, 3–5]. Prevalence
estimates for paediatric IBD range from 16 to 58 per
100,000 (see Additional file 1: Table S1 for estimates)
[6–11]. However, the reported figures are difficult to
compare due to differences in data collection and
analysis [12].
The prevalence of a disease is important for planning
of health care and allocation of clinical resources. The
prevalence of IBD in Sweden across all age groups has
been reported to be 650 per 100,000 with 1/3 seeing a
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physician and receiving treatment in a given year [13].
However, it is important to report prevalence of paediat-
ric IBD separately, since these patients are taken care of
by paediatric gastroenterologists and not adult gastroen-
terologists, since early onset IBD (IBD diagnosis
<10 years of age [14]) may have a more aggressive or
complicated clinical course [15] and since paediatric IBD
seems to have increased over time [4, 6]. In addition,
data on extra-intestinal manifestations and other
immune-mediated conditions in IBD will increase know-
ledge about the disease burden in these patients [16, 17].
The primary aim of this study was to describe the
prevalence of paediatric IBD, CD and UC in Sweden by
evaluating the impact of different register-based defini-
tions of IBD on prevalence estimates. The secondary
aim was to examine the prevalence of certain comorbidi-
ties in paediatric IBD (i.e., extra-intestinal manifesta-
tions) vs. matched general population controls.
Methods
Setting
In 2010, Sweden had a population of 1.9 million <18 years
of age (Statistics Sweden [18]). The Swedish healthcare
system is tax funded and offers universal access.
Identification of children with inflammatory bowel
disease
The Swedish National Patient Register was used to iden-
tify all patients <18 years of age in 2010 with a visit list-
ing a diagnosis of CD (ICD10 K50; ICD9 555) or UC
(ICD10 K51; ICD9 556; see supplemental digital content
(SDC), Additional file 2: Table S2). This register was
launched in 1964, became nationwide in 1987, and in-
cludes non-primary outpatient physician visits since
2001. Visits to general practitioners (i.e., primary care in
Sweden) are not included [19]. Register linkage was per-
formed using the unique personal identity number [20].
Prevalent cases of IBD were defined as children living in
Sweden in 2010 with ≥2 visits in either inpatient care
(1993–2010) or non-primary outpatient care (2001–2010,
including day surgery since 1997). Patients with listings of
both CD and UC diagnoses were included in the overall
IBD prevalence estimate and defined as IBD-U. To esti-
mate the number of children with treated disease in 2010,
we identified children with ≥2 IBD-related visits, of which
≥1 occurred in 2010 plus ≥1 dispensed drug prescription
for aminosalicylates, corticosteroids, or immunosuppres-
sants in 2010. To test the robustness of the estimates,
prevalence was also calculated according to alternative
case definitions based on the total number of visits with a
listing of CD or UC, time interval between visits, type of
diagnosis (main or contributory), IBD-related treatment.
To be able to compare results with previous reports,
prevalence was also estimated using age restrictions
(<15 years, <16 years and <17 years) [7–10].
Identification of matched general population controls
Up to six general population controls were matched by
age, sex, and county of residence to each child at the
time of first IBD diagnosis (defined as 1st registered CD
or UC diagnosis in inpatient or non-primary outpatient
care). The matched general population controls were
sampled from the Register of the Total Population [18].
This register covers the entire Swedish population and
includes information on age, sex, and place of residence
as well as dates of birth, death, and emigration status.
Medical and surgical treatment
To quantify IBD-related healthcare resource use during
the study period as well as current use in 2010, data re-
garding surgical procedures and medical treatment were
collected from the National Patient Register using surgi-
cal procedure codes see and the Prescribed Drug Regis-
ter using ATC codes.
Major surgery was defined as total colectomy, partial
excision of intestine, and partial excision of rectum and
minor intestinal surgery as dilatation of the intestine,
stricturoplasty, sphincterotomy, suture and procedure
related to fistulae, fissures or abscesses (see SDC,
Additional file 3: Table S3). Medical treatment data
included dispensed prescriptions of aminosalicylates,
corticosteroids, and immunosuppressants (see SDC,
Additional file 4: Table S4). Other IBD-related treatment
such as exclusive enteral nutrition (EEN) is not captured
in the Swedish national registers and could therefore not
be evaluated. Overall, >99% of non-infusion drug use
(including biologics) is captured in the Prescribed Drug
Register, but infusion biologics are covered to a lesser
extent (e.g., some 20% of infliximab use in 2009) [21].
We also examined dispensed prescriptions 2005–2010 as
well as during 2010 only.
Presence of other diseases
To compare the prevalence of certain other conditions
in IBD patients to matched controls, information on
those diseases considered to be extra-intestinal manifes-
tations [22] was obtained through the National Patient
Register during the study period (for a complete list see
SDC, Additional file 5: Table S5), and included rheum-
atic diseases, dermatologic diseases, hepatobiliary
diseases including primary sclerosing cholangitis, and
pancreatic diseases [22]. Presence of any of those condi-
tions during the study period (1993–2010) was obtained
using inpatient and non-primary outpatient care using
disease-specific ICD codes (≥1 visit) [17].
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Statistics
Prevalence of IBD, CD, UC, and IBD-U was defined as
the prevalence on December 31st 2010, and calculated
as the number of children (<18 years) alive and residing
in Sweden on December 31st 2010 with at least two
diagnosis listings of CD or UC during the study period
(1993–2010) divided by the total Swedish population
<18 years of age on that date (n = 1,919,094) [18]. Preva-
lence estimates of physician-diagnosed and coded
comorbidities in children with IBD (including CD, UC,
and IBD-U) and those diseases in matched controls were
compared using the chi-square test.
All statistical analyses were performed using SAS
(version 9.4, SAS Institute Inc., Cary, NC, USA).
Ethics
Ethical approval for this study was granted by the
Regional Ethics Committee, Stockholm, Sweden [23].
Permission to use the databases in this study was
granted by the two government agencies the National
Board of Health and Welfare and Statistics Sweden.
Results
In the National Patient Register, 1432 children (see SDC,
Additional file 6: Figure S1; mean age in 2010: 14 years;
standard deviation: 3; range 2–17 years; 56% boys) were
identified as having a history of at least 2 visits listing an
IBD diagnosis during the study period. Of those, 1209 chil-
dren had at least 1 IBD-related visit in 2010 and 1193 chil-
dren had at least 1 IBD-related visit in 2010 and dispensed
≥1 IBD-related drug prescriptions in 2010 (treated disease
in a given year; see SDC, Additional file 7: Figure S2).
Patient characteristics for the 1432 children are
described in Table 1 and Additional file 8: Figure S3.
Of all children with IBD, 20% had at least one recorded
comorbidity considered to represent extra-intestinal
manifestations.
Prevalence
The prevalence of paediatric IBD in 2010 was 75 per
100,000 (30 per 100,000 for UC, 29 per 100,000 CD, 16
per 100,000 for patients with IBD-U on December 31st
2010; Fig. 1a). When restricting the case definition to
children treated in 2010, the prevalence estimate was 62
per 100,000 (Fig. 1a). Disease specific prevalence esti-
mates for treated UC, CD and for patients with IBD-U
during the study period were 25 per 100,000, 23 per
100,000 and 13 per 100,000.
Sensitivity analysis (Fig. 1b; Additional file 7: Figure S2)
Requiring only 1 visit, the overall prevalence estimate of
IBD increased from 75 per 100,000 to 116 per 100,000.
Shortening the time period of data capture to 2010 re-
duced the prevalence to 63 per 100,000 (−16% compared
to the base case). Adding the requirement of a max-
imum of 6 or 12 months between the first visits, the
prevalence estimates were 69 per 100,000 and 72 per
100,000 for 6 and 12 months (−8 and −4% compared to
the base case), respectively. Requiring at least 1 IBD-
related visit every year during follow up lead to a preva-
lence of 65 per 100,000 (−14% compared to the base
case prevalence estimate).
Restricting the analysis to <17 years, as in a previous
US study [7], we estimated an IBD prevalence of 61 per
100,000. When restricting the analysis to ages <16 years
as in two previous Swedish studies [8, 9], the prevalence
decreased from 75 per 100,000 to 49 per 100,000. And
finally restricting the analysis to <15 year-old children as
in a previous Danish study [10] we found a prevalence
of 38 per 100,000.
Inflammatory bowel disease-related healthcare use
In 2010, 84% of 1432 the children had one or more IBD-
related visits in non-primary outpatient care and 22%
had at least one inpatient care admission (see Table 1).
Five percent of the 1432 children with IBD had under-
gone at least one major IBD-related surgical procedure
during the study period (1993–2010). In patients with a
major surgical procedure the mean and median time from
first recorded IBD diagnosis to first major IBD-related sur-
gery were 1.5 and 1.4 years, respectively (quartile range
0.5–2.4 years). In the total IBD cohort, the mean and me-
dian observation times from register-identification to
December 31st, 2010, were 4 and 3 years, respectively. In-
testinal surgery was the most common surgical procedure
performed in CD patients (5%), colectomy the most
common one in UC patients (3%). In 2010, 2% of the 1432
children had at least one major surgical procedure.
Medical drug treatment penetration was high with
85% of children having had at least one dispensed
prescription for aminosalicylates, corticosteroids, or im-
munosuppressants in 2010 and 93% during 2005–2010
(see Table 1).
Presence of other diseases e.g., those considered to be
extra-intestinal manifestations
IBD patients had a higher prevalence of physician-
reported dermatologic, hepatobiliary, pancreatic and
rheumatic disease than matched general population
controls (all P < 0.01; Fig. 2).
Of the conditions investigated in the 1432 IBD chil-
dren, rheumatic diseases were most common (7.2%),
followed by hepatobiliary diseases (5.5%) and dermato-
logic diseases (4.7%). A higher percentage of children
with CD than UC had dermatologic (6.8% versus 1.7%;
P < 0.01) or rheumatic diseases (8.9% vs. 4.6%; P < 0.01),
while the opposite was the case for hepatobiliary
diseases (3.1% versus 6.8%; P < 0.01).
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Discussion
The overall prevalence of paediatric IBD in 2010 was
75 per 100,000, while the prevalence of treated IBD in
2010 was estimated to be 62 per 100,000 overall, 23
per 100,000 for CD, 25 per 100,000 for UC, and 13 per
100,000 for patients with IBD-U). Extra-intestinal
manifestations were, as expected, considerably more
common in IBD than in the general population, with
rheumatic disease being the most common
comorbidity in CD (8.9%) and hepatobiliary conditions
in UC (6.8%).
Previous research
There are few prevalence studies on paediatric IBD so
far (Additional file 1: Table S1) [6–10]. A recent
Canadian study of 3169 patients found a similar preva-
lence of paediatric IBD (58.3 per 100,000) compared to
75 per 100,000 in our study [6]. In contrast a US study
[7] provided lower prevalence estimates for UC (19.5 per
100,000) and CD (12.0 per 100,000) (Additional file 1:
Table S1).
As shown in several of our sensitivity analyses, the
between-study variations likely arise from differences in
Table 1 Characteristics, medical and surgical treatment of children with register-identified inflammatory bowel disease (prevalent









Boys, n (%) 802 (56%) 319 (58%) 317 (54%) 166 (56%)
Age (y); mean (SD)
at identification 10 (4) 11 (4) 10 (4) 9 (4)
in 2010 14 (3) 14 (3) 14 (3) 14 (3)
Age groups in 2010
0–9 yearsd 156 (11%) 51 (9%) 71 (12%) 34 (11%)
10–17 years 1276 (89%) 497 (91%) 514 (88%) 265 (89%)
Presence of diseases considered to be extra-intestinal manifestations 281 (20%) 115 (21%) 91 (16%) 75 (25%)
IBD-related in- and outpatient visits in 2010
Outpatient visits 1199 (84%) 451 (82%) 492 (84%) 256 (86%)
Inpatient visits 310 (22%) 128 (23%) 121 (21%) 61 (20%)
Major IBD-related surgery
In 2010 35 (2%) 23 (4%) 7 (1%) 5 (2%)
During 1993-2010c 78 (5%) 28 (5%) 23 (4%) 27 (9%)
Colectomy 36 (3%) 1 (0.2%) 18 (3%) 17 (6%)
Intestinal surgery 45 (3%) 27 (5%) 5 (1%) 13 (4%)
Rectal surgery 6 (0.4%) 1 (0.2%) 2 (0.3%) 3 (1%)
Minor bowel surgery 83 (6%) 58 (11%) 6 (1%) 19 (6%)
IBD-related drug treatment
In 2010 1213 (85%) 443 (80%) 502 (86%) 262 (88%)
Aminosalicylates 1 065 (74%) 370 (68%) 472 (81%) 223 (75%)
Steroids 593 (41%) 203 (37%) 257 (44%) 133 (44%)
Immunosuppressants (incl. biologics)a 666 (47%) 307 (56%) 209 (36%) 150 (50%)
During 2005-2010b 1333 (93%) 500 (91%) 541 (92%) 292 (98%)
IBD = inflammatory bowel disease; Patients required to have at least two listings of the selected diagnoses to be defined as a case; Differential diagnosis defined
as Behcet’s disease, irritable bowel syndrome, intestinal tuberculosis, amoebic colitis, celiac disease, diverticulitis, ischemic colitis, non-infective colitis, radiation
damage, and infectious/bacterial colitis. Diseases with main focus on those considered to be extra-intestinal manifestations were defined as rheumatic, dermatologic,
hepatobiliary and pancreatic diseases and were based on the World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD and/or the
treatment guidelines for IBD from the Swedish Association of Gastroenterology [22, 29]. Major IBD-related surgery defined as total colectomy, partial excision of intestine, and
partial excision of rectum; IBD-related drug treatment defined as dispensed prescription of aminosalicylates, corticosteroids, immune modifiers, and biologics; Codes used for
physician-diagnosed and comorbid conditions considered to be extra-intestinal manifestations are available in the SDC, Additional file 5: Table S5; Codes used in this analysis
are available above in Additional file 3: Table S3 (surgical procedures) and Additional file 4: Table S4 (dispensed prescription drugs); Numbers do not sum up as overlap be-
tween the groups e.g., colectomy and intestinal surgery or steroids and immunosuppressants were possible
aInfusion biologics are covered to a lesser extent in the Prescribed Drug Register (e.g., about 20% of infliximab use in 2009) [21]; Given that infusion biologics are
covered to a lesser extent, this number should be interpreted with caution
bData from the Prescribed Drug Register only available since 2005 onwards
cNote that surgery after the 18th birthday is not counted and that only a minority of patients in the sample have been followed for >4 years at their 18th birthday
dEarly onset defined as with a diagnosis before 10 years of age [14]
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study methods, including case ascertainment, IBD defin-
ition, length of data capture periods, age distributions,
and age cut-off points rather than true prevalence varia-
tions. Even though our base case estimate was quite ro-
bust varying only between 62 and 75 per 100,000 when
testing the clinically most relevant algorithms and defini-
tions, the estimates increased to 116 per 100,000 when
only 1 visit was required for case definition and
decreased to 38 per 100,000 when the analysis was re-
stricted to children <15 years. The increase in prevalence
from 38 to 75 per 100,000 < 18 years can be explained
by factors such as the longer data capture period for
older children, which increases the chance of registration
of a diagnosis. Disease onset is usually more common in
older than younger children [24, 25] thus inclusion of
older adolescents will increase prevalence estimates [6].
By analysing the paediatric subgroup in more detail, we
found that only about 1/3 of all IBD patients are treated
in a given year (i.e., having had ≥2 IBD-related visits
with one visit and ≥1 dispensed IBD-related drug pre-
scription in 2010) [13], compared to 83% in children.
Also, as previously shown, the percentage of patients
with a IBD-U was 21% in children compared to 17%
overall [13].
A recent cross-sectional study using outpatient and in-
patient insurance claims data found that IBD patients
Fig. 1 a Register-based prevalence of paediatric inflammatory bowel disease, ulcerative colitis and Crohn’s disease (<18 years of age, n = 1432) for
actively monitored and treated disease in 2010 and overall in 2010. IBD = inflammatory bowel disease; UC = ulcerative colitis; CD = Crohn’s disease;
Patients required to have at least 2 listings of the selected diagnoses to be defined as a case; Treated in a given year was defined as having at
least one of the two inflammatory bowel disease-related visits occurring in 2010 and at least one inflammatory bowel disease-related dispensed
prescription in 2010. b Additional sensitivity analysis to evaluate the impact on the overall inflammatory bowel disease prevalence estimate. Estimate
based on a source population in 2010 of 1,919,094 < 18 years old, 1,794,267 < 17 years old, 1,675,031 < 16 years old and 1,564,959 < 15 years old
(www.scb.se); IBD = inflammatory bowel disease
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<20 years of age have more immune-mediated diseases
than matched controls [17]. The authors of that study
found a positive association between CD and rheuma-
toid arthritis (odds ratio [OR] 15.7, 95% CI 4.6–53.7),
systemic lupus erythematosus (OR 41.0, 95% CI 2.3–
719.1) and hypothyroidism (OR 2.9, 95% CI 1.4–6.1).
UC was associated with a higher prevalence of diabetes
(OR 2.7, 95% CI 1.1–6.6). Both in our study and in that
of Kappelman et al. [17] rheumatic diseases were the
most common extra-intestinal manifestations. In the
prospective, observational study from Dotson et al., 17%
of the included 1009 children <16 years with newly diag-
nosed IBD displayed extra-intestinal manifestations [16].
This percentage increased to 28% during follow-up
(26 months) [16]. We found that about 20% of IBD
patients <18 years of age had ≥1 physician-diagnosed
rheumatic, hepatobiliary, pancreatic or dermatologic dis-
ease. However, due to differences in definitions and
study design, results between studies are difficult to
compare. While information regarding extra-intestinal
manifestations was prospectively collected in regular
scheduled visits in the study by Dotson et al. [16], we
used register-based information to obtain the prevalence
of certain conditions in IBD patients and their matched
controls. Using registry-based information may have
underestimated their true prevalence as some gastroen-
terologists regard those diseases as being part of IBD
(i.e., extra-intestinal manifestations) and therefore do
not assign a specific ICD code for, e.g., rheumatic
disease.
Strengths
A strength of this study was the access to routinely col-
lected nationwide data on inpatient and non-primary
outpatient care, as well as dispensed prescription drugs.
The large sample size allowed us to assess variations in
prevalence and to perform sensitivity analyses. Using a
register-based approach we were able to assess the over-
all prevalence of any paediatric IBD and IBD requiring
active monitoring and treatment. The latter estimate
may be of more practical interest as it better reflects the
actual burden to the healthcare system in a given year.
The prevalence helps to describe the overall burden of a
chronic, relapsing and remitting disease such as IBD as
it includes children in remission who might be in need
of resources and care at a later point in time. Additional
strengths included that there was no need to adjust the
prevalence to allow generalizability or to extrapolate to
the general population as Swedish registers are national
and virtually complete [19].
Fig. 2 Presence of diseases considered to be extra-intestinal manifestations in prevalent children with inflammatory bowel disease (n = 1432),
ulcerative colitis (n = 585), Crohn’s disease (n = 548), IBD unclassified (n = 299) and in matched general population controls (n = 8583; matched by
age, sex, and county of residence at time of identification). * p < 0.01 for comparison between children with IBD, UC; CD or IBD-U and matched
controls; Patients required to have at least 2 listings of the selected diagnoses to be defined as a case; Rheumatic diseases defined as rheumatoid
arthritis, psoriatic and enteropathic arthropathies, juvenile arthritis, unspecified arthritis, pain in joints, Sjögrens syndrome, Behcet’s disease,
ankylosing spondylitis; Dermatologic diseases defined as pyoderma gangraenosum, erythema nodosum, psoriasis, febrile neutrophilic dermatosis,
aphthous stomatitis; Hepatobiliary diseases defined as primary sclerosing cholangitis, pericholangitis, cholelithiasis, chronic active hepatitis,
nonalcoholic fatty liver disease; Pancreatic diseases defined as acute or chronic pancreatitis; Codes used in this analysis are available in the SDC,
Additional file 5: Table S5; patients IBD-U defined as patients with both a UC and a CD diagnosis during follow up
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Limitations
A limitation of this register-based approach pertains to
the specificity and the sensitivity of our IBD definition
since our diagnoses were not validated through clinical
examinations. Although we did not have access to symp-
tom and endoscopy data to confirm the IBD diagnoses,
our earlier review on the National Patient Registry found
a positive predictive value (PPV) of 85–95% for most
diagnoses [19]. Data from patient chart reviews suggest
a PPV of 93% for ≥2 recorded diagnoses with IBD in
Sweden [26]. This is almost identical to the PPV of 92%
found when British researchers evaluated the General
Practice Research Database in 2002 [27], another source
of registry-based research.
Another limitation is that data from non-primary out-
patient care were not available for the whole study
period. However, we believe that the sensitivity of IBD in
the National Patient Register was high for children as
paediatric patients are managed by hospital-based spe-
cialists rather than general practitioners and are closely
monitored with specialist visits every 3 to 6 months
(92% of the identified children with IBD were seen every
3 to 6 months in 2010) and 1238 patients (86%) had ≥1
IBD-related visit every year during follow up. Testing
the impact of a more liberal definition defined as only
≥1 visit for the case definition increased the prevalence
estimate to 116 per 100,000 in 2010. To minimize the
risk of false positive cases, we therefore decided to use
≥2 visits in our main analysis even though this meant
that we probably excluded some true cases. An add-
itional analysis showed that of the 662 patients with only
1 visit until 2009, 7% had an additional visit in 2010
while 93% were not seen by a physician for their IBD.
Therefore, our approach most likely underestimates the
prevalence even though we consider the impact to be
small. A stricter definition such as the one used in the
Canadian study [6] was considered to be too strict as the
Swedish National Patient Register only includes in-
patient and non-primary outpatient specialist visits, and
not contacts with primary healthcare providers.
We identified a high percentage of patients with both
diagnostic codes for CD and UC registered, likely includ-
ing patients with IBD-U, indeterminate colitis, patients
who had a disease onset typical of UC and who later de-
veloped clear signs of CD or patients who even got the
wrong IBD diagnosis at some point because of a typo.
Given our lack of endoscopy or histology data, and the
fact that many patients have to be classified as IBD-U,
even with all clinical information available [28], we ana-
lysed children with both diagnoses listings during the
study period as a separate group since we could not say
with certainty which diagnoses they really had. In our pre-
vious analysis of all age-groups we analysed the impact of
re-classification of patients with both diagnoses of UC and
CD during the study period using the last 9 diagnoses and
showed that impact on the prevalence would be small
[13]. However, when trying to describe those patients in
more detail, e.g., regarding occurrence of extra-intestinal
manifestations, we excluded them due to the resulting
diagnostic ambiguity. Our higher estimate compared to
previous studies is probably partly explained by a longer
data capture period increasing the chance of getting both
diagnoses (our study had a capture period of 17 years
compared to 2–14 years in previous studies [6–8, 10]).
We had near complete coverage of dispensed non-
infusion prescriptions (including e.g., azathioprine and
adalimumab), but unfortunately were only able to identify
some 20% of infusion biologics (e.g., infliximab), which
makes it important to point out that the recorded propor-
tion of patients on infusion biologics in our dataset is
probably lower than in reality. Moreover, we were not at
all able to identify treatment with EEN in the registers.
Conclusions
In conclusion, we found a prevalence of treated paediat-
ric IBD in 2010 of 62 per 100,000 and a total prevalence
of 75 per 100,000. The prevalence was stable once ≥2 or
more IBD-related visits were required, except for age-
restricted estimates. While 93% of children were treated
with aminosalicylates, corticosteroids, or immunosup-
pressants, 5% had a history of major IBD-related surgery.
As previously observed, dermatologic, hepatobiliary,
pancreatic and rheumatic disease were more common in
IBD than in the general population.
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